<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408537</url>
  </required_header>
  <id_info>
    <org_study_id>JE0153</org_study_id>
    <nct_id>NCT01408537</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children</brief_title>
  <acronym>JE0153</acronym>
  <official_title>Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Japanese encephalitis (JE) is the main cause of viral encephalitis in many countries of Asia
      including Thailand. Estimated annual mortality ranges from10,000-15,000 deaths, while the
      total number of clinical cases is about 50,000. Of these cases, about 50% result in permanent
      neuropsychiatric sequelae. The disease occurs mostly among children aged &lt;10 years. There is
      no specific antiviral treatment for JE. Vaccination is the single most important control
      measure. This study aims to evaluate the immunogenicity and safety of inactivated Vero cell
      derived JE vaccine (Beijing P-3 strain) produced by Liaoning Cheng Da Biotechnology Co., Ltd,
      China &quot;JEVAC&quot; in Thai children.

      152 healthy Thai children aged between 1-3 years will be vaccinated with &quot;JEVAC&quot; in a dose of
      0.5 mL. subcutaneously on Day 0, 1-4 weeks later and a booster vaccination at one year
      (totally 3 doses). Two mL. of blood will be drawn on Day 0, 4 weeks after second dose, at one
      year on booster vaccination day and 4 weeks after the booster (totally 8 mL. of 13 months
      study period) for determination of JE neutralizing antibodies (PRNT50) using Beijing P3
      strain. Adverse events will be observed for 28 days after each vaccination. Serious adverse
      events will be observed throughout the study period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroconversion Rate After Primary Vaccination</measure>
    <time_frame>28 days after second dose of JEVAC</time_frame>
    <description>To determine the seroconversion rate by using neutralizing antibody (NT) against JE virus (Beijing P3 strain) JE virus from &lt;10 on before first vaccination To &gt;= 10 at 28 days after second vaccination (primary vaccination). Those who have NT titer &gt;=10 before first vaccination, will not be included in immunogenicity evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of NT After Primary and Booster Vaccination</measure>
    <time_frame>28 days after second vaccination, before and 28 days after booster vaccination with JEVAC</time_frame>
    <description>To determine the geometric mean titers (GMT) of neutralizing antibody of JEVAC 1 month after primary and then before and after booster vaccinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of Vaccine</measure>
    <time_frame>7, 14, 28 days after each vaccination and throughout the study period for local, solicited systemic, unsolicited systemic and serious adverse events, respectively</time_frame>
    <description>To determine the adverse events of JEVAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing Antibody Persistence One Year After the Primary Vaccination</measure>
    <time_frame>1 year after primary vaccination</time_frame>
    <description>To determine the neutralizing antibody persistence one year after the primary JEVAC vaccination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Encephalitis, Japanese B</condition>
  <arm_group>
    <arm_group_label>JEVAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>JEVAC</intervention_name>
    <description>Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
    <arm_group_label>JEVAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy Thai children aged 1- 3 years

          2. No previous history of JE vaccination

          3. Available for all visited schedule in the study period.

          4. Written inform consent signed by a parent or guardian

        Exclusion Criteria:

          1. Known serious underlying diseases such as nervous system, heart, kidney and liver
             diseases.

          2. Known hypersensitivity to JE vaccine composition such as human albumin, dextran 40,
             etc.

          3. Previous history of JE disease.

          4. Receive the blood component within the past 3 months,

          5. Known history of immunocompromised conditions such as HIV/AIDS, malignancy.

          6. Under treatment of immunosuppressive drugs such as systemic corticosteroid and
             anti-neoplastic drug.

          7. Febrile illness (temperature ≥37.5°C) or acute illness/infection on the day of
             vaccination

          8. Plan to leave the study area before the end of study period.

          9. Participating in other clinical trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pornthep Chanthavanich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department Tropical Pediatrics</name>
      <address>
        <city>Ratchathewi</city>
        <state>Bangkok</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <results_first_submitted>April 23, 2013</results_first_submitted>
  <results_first_submitted_qc>November 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 18, 2014</results_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Pornthep Chanthavanich</investigator_full_name>
    <investigator_title>Department of Tropical Pediatrics, Faculty of Tropical Medicine</investigator_title>
  </responsible_party>
  <keyword>inactivated Japanese encephalitis vaccine</keyword>
  <keyword>vero cell</keyword>
  <keyword>children</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The enrollment took place in 2 sites (Department of Tropical Pediatrics, Faculty of Tropical Medicine and Nopparat Rajathanee Hospital) from 3rd May 2010 to 10th August 2010. One hundred and fifty two subjects who illegible for the inclusion and exclusion criteria were enrolled in the study.</recruitment_details>
      <pre_assignment_details>There was no subject who did not get the study vaccine after informed consent was signed.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JEVAC</title>
          <description>JEVAC : Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>JEVAC</title>
          <description>JEVAC : Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.2" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate After Primary Vaccination</title>
        <description>To determine the seroconversion rate by using neutralizing antibody (NT) against JE virus (Beijing P3 strain) JE virus from &lt;10 on before first vaccination To &gt;= 10 at 28 days after second vaccination (primary vaccination). Those who have NT titer &gt;=10 before first vaccination, will not be included in immunogenicity evaluation.</description>
        <time_frame>28 days after second dose of JEVAC</time_frame>
        <population>There were 152 enrolled subjects in the study. However, 5 subjects had NT titer &gt;= 10 before first vaccination and one subject whom blood on 28days after second vaccination was not drawn due to withdrawn consent. Therefore, the number of subjects for the outcome measurement should be 146.</population>
        <group_list>
          <group group_id="O1">
            <title>JEVAC</title>
            <description>JEVAC : Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate After Primary Vaccination</title>
          <description>To determine the seroconversion rate by using neutralizing antibody (NT) against JE virus (Beijing P3 strain) JE virus from &lt;10 on before first vaccination To &gt;= 10 at 28 days after second vaccination (primary vaccination). Those who have NT titer &gt;=10 before first vaccination, will not be included in immunogenicity evaluation.</description>
          <population>There were 152 enrolled subjects in the study. However, 5 subjects had NT titer &gt;= 10 before first vaccination and one subject whom blood on 28days after second vaccination was not drawn due to withdrawn consent. Therefore, the number of subjects for the outcome measurement should be 146.</population>
          <units>percentage of seroconversion</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of NT After Primary and Booster Vaccination</title>
        <description>To determine the geometric mean titers (GMT) of neutralizing antibody of JEVAC 1 month after primary and then before and after booster vaccinations.</description>
        <time_frame>28 days after second vaccination, before and 28 days after booster vaccination with JEVAC</time_frame>
        <population>152 were enrolled, 1 withdrawn consent before second vaccine, 5 had NT &gt;= 10 before first vaccine, 146 included in D28 after second vaccine. At 1 year, 3 received JE vaccine outside the study, 3 lost follow up, 140 included in before booster, At D28 after booster, 1 could not draw blood, 139 included in D28 after booster.</population>
        <group_list>
          <group group_id="O1">
            <title>GMT of NT on 28days After Vaccination</title>
            <description>GMT of NT titer of subjects on 28 days after vaccination (excluded the subject who had NT titer &gt; =10 before first vaccination).</description>
          </group>
          <group group_id="O2">
            <title>GMT of NT Before Booster Vaccine</title>
            <description>GMT of NT of subject at 1 year before booster vaccination. Exclude NT titer &gt;=10 before first vaccination and subjects received JE vaccine outside the study.</description>
          </group>
          <group group_id="O3">
            <title>GMT of NT Titer After Booster Vaccine</title>
            <description>GMT of NT of subject at 28 days after booster vaccination. Exclude NT titer &gt;=10 before first vaccination and subjects received JE vaccine outside the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of NT After Primary and Booster Vaccination</title>
          <description>To determine the geometric mean titers (GMT) of neutralizing antibody of JEVAC 1 month after primary and then before and after booster vaccinations.</description>
          <population>152 were enrolled, 1 withdrawn consent before second vaccine, 5 had NT &gt;= 10 before first vaccine, 146 included in D28 after second vaccine. At 1 year, 3 received JE vaccine outside the study, 3 lost follow up, 140 included in before booster, At D28 after booster, 1 could not draw blood, 139 included in D28 after booster.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.01" lower_limit="126.4" upper_limit="175.7"/>
                    <measurement group_id="O2" value="49.33" lower_limit="39.0" upper_limit="62.4"/>
                    <measurement group_id="O3" value="621.66" lower_limit="510.4" upper_limit="757.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events of Vaccine</title>
        <description>To determine the adverse events of JEVAC</description>
        <time_frame>7, 14, 28 days after each vaccination and throughout the study period for local, solicited systemic, unsolicited systemic and serious adverse events, respectively</time_frame>
        <population>Determined AEs by number of injections 152 injection for the first dose 151 injection for the second dose 145 injection for the third dose</population>
        <group_list>
          <group group_id="O1">
            <title>Fever After Vaccination</title>
            <description>Fever (Temp &gt; =37.5 Axillary )after each vaccinations (3 doses). Episode of fever was collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Local AE JEVAC After Vaccination</title>
            <description>Local Adverse event (tenderness, redness, ecchymosis, hematoma and swelling) after each vaccinations the first vaccination was on day of enrollment, the second dose was Day7 (+21day))
, Booster vaccine was on 1 year(+30days). Local AEs were collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O3">
            <title>Chills After Vaccination</title>
            <description>Chills after each vaccinations (3 doses). Episode of chills was collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O4">
            <title>Poor Appetite After Vaccination</title>
            <description>Poor appetite after each vaccinations (3 doses). Episode of poor appetite was collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O5">
            <title>Vomiting After Vaccination</title>
            <description>Vomiting after each vaccinations (3 doses). Episode of vomiting was collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O6">
            <title>Urticaria After Vaccination</title>
            <description>Urticaria after each vaccinations (3 doses). Episode of Urticaria was collected up to 28 days after each vaccination.</description>
          </group>
          <group group_id="O7">
            <title>Unsolicited AEs After Each Vaccination</title>
            <description>unsolicited AEs after each vaccinations (3 doses). Episode of unsolicited AEs (excluded SAEs) were collected up to 28 days after each vaccination</description>
          </group>
          <group group_id="O8">
            <title>SAEs Entire the Study</title>
            <description>SAEs which occured entire the study period were recorded.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events of Vaccine</title>
          <description>To determine the adverse events of JEVAC</description>
          <population>Determined AEs by number of injections 152 injection for the first dose 151 injection for the second dose 145 injection for the third dose</population>
          <units>events</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="152"/>
                <count group_id="O5" value="152"/>
                <count group_id="O6" value="152"/>
                <count group_id="O7" value="152"/>
                <count group_id="O8" value="152"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>injections</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="448"/>
                <count group_id="O2" value="448"/>
                <count group_id="O3" value="448"/>
                <count group_id="O4" value="448"/>
                <count group_id="O5" value="448"/>
                <count group_id="O6" value="448"/>
                <count group_id="O7" value="448"/>
                <count group_id="O8" value="448"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutralizing Antibody Persistence One Year After the Primary Vaccination</title>
        <description>To determine the neutralizing antibody persistence one year after the primary JEVAC vaccination.</description>
        <time_frame>1 year after primary vaccination</time_frame>
        <population>The analysis was excluded 5 subjects who had NT titer &gt;10 on D0</population>
        <group_list>
          <group group_id="O1">
            <title>JEVAC</title>
            <description>JEVAC : Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
          </group>
        </group_list>
        <measure>
          <title>Neutralizing Antibody Persistence One Year After the Primary Vaccination</title>
          <description>To determine the neutralizing antibody persistence one year after the primary JEVAC vaccination.</description>
          <population>The analysis was excluded 5 subjects who had NT titer &gt;10 on D0</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In addition to systematic assessment on Day 0-14 after each vaccination, Any unsolicited AE was accessed within 28 days after each vaccination. Any SAE was accessed through the study period (1 yr +28 days).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>JEVAC</title>
          <description>JEVAC : Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection (other)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">poor appetite</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">vomiting</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">Fever</sub_title>
                <description>Axillary temperature greater than or equal 37.5 celsius</description>
                <counts group_id="E1" events="79" subjects_affected="64" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>contact dermatitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (10.0)">urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Pornthep Chanthavanich</name_or_title>
      <organization>Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Thailand</organization>
      <phone>6623549161</phone>
      <email>tmpct@mahidol.ac.th</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

